Rubius Therapeutics (Nasdaq: RUBY) announced the completion of the first dosing cohort in its Phase 1/2 clinical trial for RTX-240, an allogeneic therapy for relapsed/refractory solid tumors, with no adverse events reported. The trial will assess immune responses, including NK and T cell activation, and measure anti-tumor activity. Additionally, the company will undergo a management transition as CFO Andrew Oh departs by December 31, 2020, after significantly contributing to capital raising and securing clinical supplies.
Rubius Therapeutics (Nasdaq: RUBY) presented promising preclinical data for RTX-321, its lead artificial antigen-presenting cell therapy for HPV 16-positive cancers, at the AACR Virtual Annual Meeting II. These findings suggest RTX-321 may promote epitope spreading, potentially enhancing immune responses against tumor antigens. Additionally, RTX-321 shows promise in inducing tumor-specific memory, which could provide long-term protection against recurrence. The company plans to file an Investigational New Drug application for RTX-321 by the end of 2020, signaling its commitment to advancing this innovative treatment.
Rubius Therapeutics (Nasdaq: RUBY) announced that CEO Pablo J. Cagnoni, M.D. will engage in a fireside chat at the Jefferies Virtual 2020 Healthcare Conference on June 2, 2020, at 1:00 p.m. ET. The session will focus on the company's development of a new class of cellular medicines known as Red Cell Therapeutics™, aimed at treating cancer and autoimmune diseases. A live audio webcast of the event will be available on the company’s website, along with an archived replay for 90 days post-event.
Rubius Therapeutics (Nasdaq: RUBY) announced plans to present preclinical data on its artificial antigen-presenting cell program, RTX-321, targeting HPV 16-positive cancers at the AACR Virtual Annual Meeting II from June 22-24, 2020. Laurence Turka, M.D., highlighted that HPV 16 is linked to 70% of cervical cancers and significant head and neck cancers, showcasing the unmet need for innovative therapies. Data will demonstrate RTX-321's ability to activate tumor-specific T cells and stimulate anti-tumor responses, with an Investigational New Drug application expected by year-end 2020.
Rubius Therapeutics (RUBY) presented promising preclinical data for RTX-321, targeting HPV 16-positive tumors, at the American Society of Gene and Cell Therapy Annual Meeting. The data showed significant expansion of effector and memory CD8+ T cells, crucial for effective anti-tumor immune responses. Additionally, RTX-321 can enhance both naïve and exhausted CD4+ T cells, which play a vital role in coordinating immune responses. The company plans to file an Investigational New Drug application for RTX-321 by the end of 2020, marking a critical step in its therapeutic development.
Rubius Therapeutics, Inc. (Nasdaq:RUBY) announced a strategic reprioritization of its pipeline to focus on oncology and autoimmune therapies. The company dosed its first patient in the Phase 1/2 trial of RTX-240 for advanced solid tumors. With an operational manufacturing facility and a cash position of $241.4 million, Rubius has sufficient resources to sustain operations into 2022. The first quarter 2020 net loss was $48.5 million, up from $32.6 million in Q1 2019, primarily due to increased R&D investments.
Rubius Therapeutics (Nasdaq: RUBY) announced the dosing of its first patient in the Phase 1/2 clinical trial of RTX-240, aimed at treating relapsed/refractory or locally advanced solid tumors. RTX-240 is an allogeneic Red Cell Therapeutic designed to stimulate immune responses against tumors. The study will evaluate safety, tolerability, and pharmacodynamics, with a focus on NK and T cell activation. The company is collaborating with oncology-focused centers to maximize patient enrollment while maintaining safety standards amid the COVID-19 pandemic.
Rubius Therapeutics (Nasdaq:RUBY) will announce its first quarter 2020 financial results on May 11, 2020, before the market opens. The company specializes in genetically engineered red blood cells to develop Red Cell Therapeutics™ for treating various diseases, notably cancer and autoimmune conditions. Notably, Rubius will not hold a teleconference following the release of its financial results. The company utilizes its proprietary RED PLATFORM® to create off-the-shelf therapies aimed at specific therapeutic areas. For more details, visit www.rubiustx.com.